| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/05/2001 | DE19945522A1 Pharmazeutisches, wirkstoffhaltiges Gel A pharmaceutical gel containing active ingredients |
| 04/05/2001 | DE19939566C1 Verzweigte, weitgehend ungesättigte Esteröle, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von kosmetischen und/oder pharmazeutischen Zubereitungen Branched, substantially unsaturated ester oils, process for their preparation and their use for the production of cosmetic and / or pharmaceutical preparations |
| 04/05/2001 | DE10046508A1 Magnetic nanoparticles carrying specific binding agent reactive with intracellular molecule, useful for separating cells, particularly cancerous, and biomolecules |
| 04/05/2001 | CA2616210A1 Influenza vaccine compositions |
| 04/05/2001 | CA2388474A1 Vasopressin antagonist formulation and process |
| 04/05/2001 | CA2388471A1 Pharmaceutical carrier formulation |
| 04/05/2001 | CA2388438A1 Stable calcitriol solution for packaging in vials |
| 04/05/2001 | CA2386014A1 Influenza vaccine |
| 04/05/2001 | CA2385990A1 Compositions having improved stability |
| 04/05/2001 | CA2385989A1 Compositions of tocol-soluble therapeutics |
| 04/05/2001 | CA2385971A1 Vasopressin agonist formulation and process |
| 04/05/2001 | CA2385888A1 Engineering antibodies that bind irreversibly |
| 04/05/2001 | CA2385749A1 Melt granulated composition and modified release dosage form prepared from said composition |
| 04/05/2001 | CA2385593A1 Antibody-dye conjugates for angiogenesis target structures for intraoperative tumor edge visualization |
| 04/05/2001 | CA2385498A1 Method to enhance healing of sternum after sternotomy |
| 04/05/2001 | CA2385252A1 Anti cancer agent and method of treatment of cancer |
| 04/05/2001 | CA2384814A1 Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor |
| 04/05/2001 | CA2384509A1 Scar treatment composition |
| 04/04/2001 | EP1088555A1 Sustained-release preparation |
| 04/04/2001 | EP1088554A1 Controlled release drug association containing 5-isosorbide mononitrate and acetylsalicylic acid |
| 04/04/2001 | EP1088547A2 Combinations of active substances respectively adducts from biotin and/or biotin derivatives with cyclodextrins and use of such combinations of active substances in cosmetic preparations |
| 04/04/2001 | EP1088486A2 Stable powder compositions comprising vitamins and/or carotenoids and their preparation |
| 04/04/2001 | EP1088315A1 Nucleation and growth of magnetic metal oxide nanoparticles and its use |
| 04/04/2001 | EP1088059A1 A polypeptide-polymer conjugate |
| 04/04/2001 | EP1087989A1 Improved process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon |
| 04/04/2001 | EP1087800A1 Medical device having anti-infective and contraceptive properties |
| 04/04/2001 | EP1087791A1 Inhibition of xenoreactive antibodies |
| 04/04/2001 | EP1087786A1 Methods and materials for the treatment of prostatic carcinoma |
| 04/04/2001 | EP1087783A2 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF $i(HELICOBACTER PYLORI)-ASSOCIATED DISORDERS |
| 04/04/2001 | EP1087781A1 Dietary supplement for supporting cerebrovascular tone |
| 04/04/2001 | EP1087778A1 Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
| 04/04/2001 | EP1087773A1 Vaginal active agent delivery procedures and formulations thereof |
| 04/04/2001 | EP1087757A1 Method for making tablets with active principle sustained-release |
| 04/04/2001 | EP1087754A1 Method of forming liposomes |
| 04/04/2001 | EP1087753A1 Targeted liposomal drug delivery system |
| 04/04/2001 | EP1087751A1 Active ingredient delivery systems and devices based on porous matrices |
| 04/04/2001 | EP1018340A9 Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them |
| 04/04/2001 | EP0954274A4 Topical product formulations containing strontium for reducing skin irritation |
| 04/04/2001 | EP0788515B1 Non-antigenic branched polymer conjugates |
| 04/04/2001 | EP0741734B1 Phenylboronic acid complexes |
| 04/04/2001 | CN1290180A Sterile complex of therapeutic peptide bond to polysaccharide |
| 04/04/2001 | CN1290178A Transfection particles |
| 04/04/2001 | CN1290177A Crystallographically stable amorphous sephalosporin compositions and process for producing the same |
| 04/04/2001 | CN1290174A Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| 04/04/2001 | CN1290171A Composition and method for regulating cell proliferation and cell death |
| 04/04/2001 | CN1290167A Dried or frozen pharmaceutical prepartion containing class III antiarrhythmic compound |
| 04/04/2001 | CN1063971C Method for preparing freeze-dried live vaccine for animal use |
| 04/04/2001 | CN1063941C Stable compositons for parenteral administration and method of making same |
| 04/03/2001 | US6211349 Protonated/acidified nucleic acids and methods of use |
| 04/03/2001 | US6211342 Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| 04/03/2001 | US6211273 Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules |
| 04/03/2001 | US6211250 Percutaneous delivery system |
| 04/03/2001 | US6211243 Methods for treating cold sores with anti-infective compositions |
| 04/03/2001 | US6211238 Drugs, fungicides and preservatives |
| 04/03/2001 | US6211171 Administering tricyclic amitriptyline and desipramine to treat neuropathic pain |
| 04/03/2001 | US6211169 Stable calcitriol solution for packaging into vials |
| 04/03/2001 | US6211162 Pulmonary delivery of protonated/acidified nucleic acids |
| 04/03/2001 | US6211152 Formulations for peptide release |
| 04/03/2001 | US6211144 Stable concentrated insulin preparations for pulmonary delivery |
| 04/03/2001 | US6210742 Emulsions are suited for preparation of food products, personal care products, pharmaceutical products and industrial products |
| 04/03/2001 | US6210717 System for transporting genes into eukaryotic cells; used for transforming targeted host cell |
| 04/03/2001 | US6210709 Plant based starch having been modified to have gelatin like properties; and a paint ball formulation, drug, vitamin, perfume or bath product contained within the capsule. |
| 04/03/2001 | US6210708 Cationic virosomes as transfer system for genetic material |
| 04/03/2001 | US6210707 Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| 04/03/2001 | US6210705 Flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours. |
| 04/03/2001 | US6210703 Glass fiber chemical delivery system |
| 04/03/2001 | US6210698 Suppository composition |
| 04/03/2001 | US6210683 Stabilizers containing recombinant human serum albumin for live virus vaccines |
| 04/03/2001 | US6210677 Method to reduce the physiologic effects of drugs on mammals |
| 04/03/2001 | US6210672 Topical immunostimulation to induce Langerhans cell migration |
| 04/03/2001 | US6210343 Use of misoprostol or/and misoprostol acid for diagnosis of vascular damage in a subject with erectile dysfunction |
| 04/03/2001 | CA2210996C Liquid formulations for proteinic pharmaceuticals |
| 04/03/2001 | CA2210823C Pharmaceutical compositions comprising lactobacilli suitable for trans-mucosal administration |
| 04/03/2001 | CA2074186C Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| 03/29/2001 | WO2001021656A2 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 03/29/2001 | WO2001021297A1 Polydisperse double emulsion, corresponding monodisperse double emulsion and method for preparing the monodisperse emulsion |
| 03/29/2001 | WO2001021259A2 Use and compositions for treating platelet-related disorders using anagrelide |
| 03/29/2001 | WO2001021217A2 Method of treating cells of the prostate prophylactically or therapeutically |
| 03/29/2001 | WO2001021213A2 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | WO2001021212A1 A stable product of isohexylnaphthazarins with penta- and tetra-cyclic triterpenes |
| 03/29/2001 | WO2001021211A2 Process for lessening polymorphic conversion of a drug |
| 03/29/2001 | WO2001021210A1 Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | WO2001021209A1 Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | WO2001021207A2 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | WO2001021197A1 Synthesis of insulin derivatives |
| 03/29/2001 | WO2001021196A1 Method and compositions for inhibiting adhesion formation |
| 03/29/2001 | WO2001021193A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | WO2001021189A1 Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| 03/29/2001 | WO2001021179A1 Quetiapine granules |
| 03/29/2001 | WO2001021175A1 Antibacterial medicinal compositions |
| 03/29/2001 | WO2001021171A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 03/29/2001 | WO2001021170A1 Systems for delivering anti-infective compositions from frangible ampules to treat disordered tissue such as cold sores |
| 03/29/2001 | WO2001021163A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/29/2001 | WO2001021159A2 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 03/29/2001 | WO2001021157A2 Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury |
| 03/29/2001 | WO2001021156A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | WO2001021155A1 Cushioning wax beads for making solid shaped articles |
| 03/29/2001 | WO2001021154A2 Surface modified particulate compositions of biologically active substances |
| 03/29/2001 | WO2001021153A2 Pharmaceutical gel containing active substances |
| 03/29/2001 | WO2001021152A1 Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |